ZyVersa Therapeutics' CEO, Stephen C. Glover to Attend the 38th Annual J.P. Morgan Healthcare Conference 2020HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)ZyVersa Therapeutics' CEO, Stephen C. Glover to Attend the 38th Annual J.P. Morgan Healthcare Conference 2020PR NewswireJanuary 6, 2020ReblogShareTweetShareZyVersa's lead renal candidate is VAR 200, a cholesterol efflux mediator for treatment of renal disease; Phase 2a clinical trial scheduled to begin Q1-2020 in patients with FSGSZyVersa's lead anti-inflammatory candidate, IC 100, is a novel monoclonal antibody that inhibits the ASC component of multiple types of inflammasomes, with potential to treat numerous inflammatory conditionsWESTON, Fla., Jan. 6, 2020 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and President, will attend the 38th Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2020, at the Westin St. Francis Hotel in San Francisco.(PRNewsfoto/Variant Pharmaceuticals, Inc.)MoreThe J.P. Morgan Healthcare Conference is Wall Street's premier investor conference focused exclusively on companies defining the healthcare industry.  It is the largest and most informative healthcare investment symposium in the industry.About ZyVersa Therapeutics, Inc.ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our clinical pipeline includes a phase 2a-ready asset, VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS), and a novel inflammasome inhibitor with potential to treat multiple inflammatory diseases. For more information, please visit ZyVersa.com.CisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/zyversa-therapeutics-ceo-stephen-c-glover-to-attend-the-38th-annual-jp-morgan-healthcare-conference-2020-300981118.htmlSOURCE ZyVersa Therapeutics, Inc.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextDoctor on Running Coronavirus Drug Trials: ‘You Go, Man’The Daily BeastGilead starts two late-stage studies to test drug for coronavirusReutersBiotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM BioZacksNovavax is working to advance a potential coronavirus vaccine. So are competitors.American City Business JournalsThis Man Lost 42 Pounds So He Could Donate a Kidney to His BrotherMen's HealthBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoKorea Cases Top 2,000; Nigeria Confirms Infection: Virus UpdateBloombergStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video